Drug Combination Disappoints in Advanced NSCLC Drug Combination Disappoints in Advanced NSCLC

Second-line bevacizumab plus osimertinib showed some PFS benefit over osimertinib alone in a subset of smokers/former smokers but overall showed no survival benefits in the ETOP BOOSTER trial.Medscape Medical News
Source: Medscape Hematology-Oncology Headlines - Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news